Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Inclusion Criteria: * Histologically confirmed relapsed or refractory solid tumor or lymphoma including: * Neuroblastoma * Osteosarcoma * Ewing's sarcoma * Rhabdomyosarcoma * Wilms tumor * CNS tumors * Histological verification not required for brainstem tumors * No acute leukemia * Not eligible for higher priority COG phase I/II study * Performance status - Karnofsky 50-100% (over age 10) * Performance status - Lansky 50-100% (age 10 and under) * At least 2 months * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 75,000/mm\^3 (transfusion independent) * Hemoglobin at least 8.0 g/dL (transfusion allowed) * No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement * Bilirubin no greater than 1.5 times normal * SGPT no greater than 5 times normal * Albumin at least 2 g/dL * Creatinine no greater than 1.5 times normal * Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal * Shortening fraction at least 27% by echocardiogram * Ejection fraction at least 50% by MUGA * Stable neurologic deficits within the past 2 weeks for patients with CNS tumors * CNS toxicity less than grade 2 * No active graft-versus-host disease * No active uncontrolled infection or other serious medical condition * No uncontrolled diabetes mellitus * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * At least 7 days since prior biologic therapy and rec…